Key result
Lipid-lowering therapy increases fibrous cap thickness by ~67 μm, with greater gains at lower LDL-C.
Why the study?
Does lipid-lowering therapy improve coronary atherosclerotic plaque stability and progression in East Asian individuals?
Meta-Analysis
Does lipid-lowering therapy improve coronary atherosclerotic plaque stability and progression in East Asian individuals?
Answers are grounded in this paper and cite their sources.
Lipid-lowering therapy, particularly intensive therapy targeting LDL-C <55 mg/dL, improves coronary plaque stability and regression in East Asian patients.
BACKGROUND: Lipid-lowering therapy (LLT) is important to control atherosclerosis and prevent atherosclerotic cardiovascular disease (ASCVD) events. OBJECTIVES: This study aimed to summarize the effects of LLT on coronary atherosclerotic plaque stability and progression in East Asian individuals. METHODS: A systematic literature search was performed from respective inception dates to November 21, 2023. Studies carried out on East Asian participants who received LLT were included. Meta-analysis and meta-regression analysis were used to investigate the effects of LLT on plaque regression indicators and plaque stabilization indicators (PROSPERO registration number CRD42024504184). RESULTS: = 0%) of percent atheroma volume when compared with levels in the range of 55 to 70, 70 to 100, and 100 to 130 mg/dL. LLT resulted in a pooled fibrous cap thickness gain of 66.90 μm (95% CI: 50.06-83.75 μm) at the end of the follow-up. There was a trend that decreasing follow-up LDL-C levels were associated with larger increases of fibrous cap thickness, especially when LCL-C was <70 mg/dL. CONCLUSIONS: LLT is beneficial for East Asian patients with established ASCVD or with higher risks of ASCVD. Intensive LLT with a lower target LDL-C, especially to <55 mg/dL, would be beneficial for atherosclerosis treatment.
No takes yet. Share an insight, caveat, or question.
Fujisaki et al. (2025) conducted a meta-analysis in Coronary atherosclerotic plaque. Lipid-lowering therapy was evaluated on Fibrous cap thickness gain (MD 66.90 μm, 95% CI 50.06-83.75). Lipid-lowering therapy resulted in a pooled fibrous cap thickness gain of 66.90 μm in East Asian individuals, with larger increases associated with lower follow-up LDL-C.
Synapse has enriched 10 related papers. Consider them for comparative context: